WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by South Korea's Ministry...
January 18, 2022
by prnasia
ImmuneOncia, WuXi Biologics partner for bispecific antibody development
ImmuneOncia Therapeutics has signed a Memorandum of Understanding (MoU) with WuXi Biologics to develop and manufacture bispecific antibody, IOH-001.
December 30, 2021
by Pharmaceutical-Technology
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the ...
August 3, 2021
by prnasia
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
WuXi Biologics announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany.
July 27, 2021
by prnasia
WuXi Biologics Receives Manufacturing License from German Health Authorities
The inspections comprised areas of cGMP manufacturing required for receiving the permit, as well as commercial production approval.
July 27, 2021
by contractpharma
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
WuXi Biologics, a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract ...
May 27, 2021
by prnasia
Duality Biologics Completed $90 Million Series B Financing
Duality Biologics, an innovative biotech company, announced the completion of $90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested by YUNION Healthcare Fund, Huagai Capital ...
May 20, 2021
by prnasia
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
WuXi Biologics, a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end contract development ...
May 14, 2021
by prnasia
2020 Results Record High Despite a Challenging Year
WuXi Biologics announces its audited annual results for the year ended December 31, 2020.
March 24, 2021
by CHhIChina
WuXi Biologics to acquire CMAB Biopharma Group
WuXi Biologics announced it has entered into a purchase agreement with CBC Group (CBC), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90 per cent interest of CMAB ...
March 19, 2021
by expresspharma
WuXi Biologics to Acquire Manufacturing Facilities from Pfizer China
WuXi Biologics has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
March 18, 2021
by contractpharma
BioVaxys, Wuxi Biologics Enter Bioproduction Agreement
BioVaxys Technology, a provider of haptenized protein vaccines for antiviral and cancer applications, has entered into a major bioproduction agreement with WuXi Biologics, a global contract development and manufacturing organization (CDMO) and ...
March 16, 2021
by contractpharma